Drug Type Monoclonal antibody |
Synonyms Anti STT-003 Ab, Anti-butyrophilin 1A1 mAb(STCube/MD Anderson Cancer Center), HSTC 810 + [2] |
Target |
Action inhibitors |
Mechanism BTN1A1 inhibitors(butyrophilin subfamily 1 member A1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Metastatic Colorectal Carcinoma | Phase 2 | South Korea | 09 Jun 2025 | |
Extensive stage Small Cell Lung Cancer | Phase 2 | United States | 13 Feb 2024 | |
Head and Neck Neoplasms | Phase 2 | South Korea | - | |
Head and Neck Neoplasms | Phase 2 | - | - | |
Lung Cancer | Phase 2 | South Korea | - | |
Advanced Malignant Solid Neoplasm | Phase 1 | United States | 18 Apr 2022 |
Phase 1 | Colonic Cancer BTN1A1 | YAP1 | - | fwehghcqkr(mhyretayha) = Treatment with hSTC810 demonstrated a favorable safety profile, with the most common adverse events being low-grade fatigue and infusion-related reactions rwdvladnyv (alvvqgkvoi ) View more | Positive | 30 Apr 2025 | ||
Phase 1 | Colonic Cancer BTN1A1 | 47 | (all cohorts) | bzbbmjvegr(bfcvzitlgb) = flhxvfegqt cianqzyjct (iegrvpndxl ) View more | Positive | 23 Jan 2025 | |
bzbbmjvegr(bfcvzitlgb) = xsxheznaep cianqzyjct (iegrvpndxl ) View more | |||||||
Phase 1 | 12 | ejzkaxfcte(zwyvvwklof) = ehsxivtdqj lxhfaecnom (vyzaisclkz ) | Positive | 23 Jan 2025 | |||
Phase 1 | Advanced Malignant Solid Neoplasm BTN1A1 | PD-L1 | 47 | xxjjtlaeko(ratpvnobgp) = showed a linear PK and consistent exposure ygybjqbkan (ofdgcjntwy ) | Positive | 05 Nov 2024 | ||
Phase 1 | 39 | STC810 | ylvdsbuamp(mreeewtmqs) = dnktxvnqlk ddarnnagtx (jtdbzppqnu ) View more | Positive | 26 May 2023 |